Abstract | OBJECTIVE: METHODS: RESULTS: Bioavailable testosterone levels were: 2.58 +/- 0.58 nmol/l at baseline, compared with 3.35 +/- 0.31 nmol/l at week 14 (P < 0.001) after treatment compared with 2.6 +/- 0.18 nmol/l and 2.44 +/- 0.18 nmol/l in the placebo group (P was not significant). There was no change in fibrinogen (3.03 +/- 0.18 g/l at baseline and 3.02 +/- 0.18 g/l at week 14, P = 0.24), tPA activity (26.77 +/- 4.9 Iu/ml and 25.67 +/- 4.4 Iu/ml, P = 0.88) or PAI-1 activity (0.49 +/- 0.85 Iu/ml and 0.36 +/- 0.06 Iu/ml, P = 0.16) with active treatment and no differences between the groups (at week 14, P value 0.98, 0.59 and 0.8 for fibrinogen, PAI-1 and tPA respectively). Haemoglobin concentration did not change over time, in the testosterone group (1.44 +/- 0.02 g/l and 1.45 +/- 0.02 g/l, P = 0.22). CONCLUSION: Physiological testosterone replacement does not adversely affect blood coagulation status.
|
Authors | A M Smith, K M English, C J Malkin, R D Jones, T H Jones, K S Channer |
Journal | European journal of endocrinology
(Eur J Endocrinol)
Vol. 152
Issue 2
Pg. 285-91
(Feb 2005)
ISSN: 0804-4643 [Print] England |
PMID | 15745938
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Androgens
- Plasminogen Activator Inhibitor 1
- Testosterone
- Fibrinogen
- Tissue Plasminogen Activator
|
Topics |
- Administration, Cutaneous
- Androgens
(administration & dosage, blood)
- Angina Pectoris
(epidemiology, metabolism)
- Blood Coagulation
(drug effects)
- Chronic Disease
- Fibrinogen
(metabolism)
- Humans
- Male
- Middle Aged
- Plasminogen Activator Inhibitor 1
(blood)
- Risk Factors
- Testosterone
(administration & dosage, blood)
- Thrombosis
(epidemiology)
- Tissue Plasminogen Activator
(blood)
|